深圳翰宇药业股份有限公司
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 2003-04-02
- Employees
- 429
- Market Cap
- -
- Website
- www.hybio.com.cn
- Introduction
The company was founded in April 2003 and is a national high-tech enterprise specializing in research, production and marketing of peptide drugs. The company was listed on the Shenzhen Stock Exchange in 2011 and is the earliest listed peptide pharmaceutical company in China. The company's main business is the production and sale of peptide APIs. The company's main products include peptide preparations, peptide raw materials, customer-specific peptides, cosmetic peptides, solid pharmaceutical preparations, medical devices, peptide skin care products, health products, etc. Company Honors: National High-tech Enterprise, National Advanced Technology Industrialization Demonstration Project, 2010 China's Top 200 Potential Enterprises, etc.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
63
Drug Approvals
Ganirelix Acetate Injection
- Product Name
- 醋酸加尼瑞克注射液
- Approval Number
- 国药准字H20243797
- Approval Date
- May 21, 2024
Terlipressin for Injection
- Product Name
- 注射用特利加压素
- Approval Number
- 国药准字H20093804
- Approval Date
- Mar 4, 2024
Thymalfasin for Injection
- Product Name
- 注射用胸腺法新
- Approval Number
- 国药准字H20193037
- Approval Date
- Nov 27, 2023
Sitagliptin Phosphate and metformin Hydrochloride Tablets(Ⅱ)
- Product Name
- 西格列汀二甲双胍片(Ⅱ)
- Approval Number
- 国药准字H20233025
- Approval Date
- Jan 10, 2023
Pramipexole Dihydrochloride Sustained Release Tablets
- Product Name
- 盐酸普拉克索缓释片
- Approval Number
- 国药准字H20213752
- Approval Date
- Sep 30, 2021
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next